新聞/Reuters/Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision To Uphold Approval Of Two Generic Versions Of HetliozVanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision To Uphold Approval Of Two Generic Versions Of HetliozRefinitiv閱讀少於1分鐘VNDAVanda Pharmaceuticals Inc VNDA:VANDA SEEKS FDA COMMISSIONER REVIEW OF OUTGOING CDER DIRECTOR'S DECISION TO UPHOLD APPROVAL OF TWO GENERIC VERSIONS OF HETLIOZ®Reuters美國股票© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html顯示更多登入或建立一個永久免費帳戶來閱讀此新聞讓我們開始吧
